Literature DB >> 28511782

Prevalence of early repolarization pattern in patients with lone atrial fibrillation.

Patrick W McNair1, Dan M Benenson2, James E Ip3, George Thomas3, Jim W Cheung3, Christopher F Liu3, Bruce B Lerman3, Steven M Markowitz4.   

Abstract

BACKGROUND: The objective of this study was to test the association of early repolarization pattern (ER) with lone atrial fibrillation (AF).
METHODS: Electrocardiograms (ECGs) were analyzed in blinded fashion in a case-control study of 182 patients with lone AF and 182 controls without AF.
RESULTS: Patients with lone AF and controls had similar frequencies of ER pattern (15% vs. 19%, p=0.40). In patients <50years of age, there was also no difference in the percentage of patients with ER in the AF and control groups (17% vs. 19%, p=0.60). ER pattern was more common in patients with ECG voltage criteria of left ventricular hypertrophy (LVH), with ER present in 57% of patients with elevated Sokolow-Lyon voltage compared to 14% of those without (p<0.0001).
CONCLUSIONS: No association could be identified between the ER pattern and lone AF in young and middle-aged patients. In this age group, ER is substantially more common in patients with elevated Sokolow-Lyon voltage criteria.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation; Early repolarization; Left ventricular hypertrophy

Mesh:

Year:  2017        PMID: 28511782     DOI: 10.1016/j.jelectrocard.2017.04.020

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  2 in total

Review 1.  Atrial Fibrillation in Inherited Channelopathies.

Authors:  Baha'a Al-Azaam; Dawood Darbar
Journal:  Card Electrophysiol Clin       Date:  2021-01-08

2.  Atrial Fibrillation-triggered Ventricular Fibrillation in a Patient with Early Repolarization Syndrome.

Authors:  Masaki Takahashi; Hidekazu Kondo; Keisuke Yonezu; Tetsuji Shinohara; Mikiko Nakagawa; Naohiko Takahashi
Journal:  Intern Med       Date:  2021-11-13       Impact factor: 1.282

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.